This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Oxymetazoline hydrochloride

Dosage Form; Route: Cream; topical

Recommended Studies: Two options: (1) in vitro studies or (2) an in vivo study with clinical endpoint

1. Option 1: In vitro studies

To qualify for the in vitro option to demonstrate bioequivalence for oxymetazoline hydrochloride topical cream, 1% the following criteria should be met:

A. The test product should contain no difference in inactive ingredients or in other aspects of the formulation relative to the reference product in the same packaging configuration (tube or pump) that may significantly affect the local or systemic availability of the active ingredient. For example, if the test and reference products are qualitatively (Q1) and quantitatively (Q2) the same, as defined in the guidance for industry ANDA Submissions – Refuse-to-Receive Standards and the criteria below are also satisfied, the bioequivalence of the test product with respect to the reference product may be established using a characterization based (in vitro) bioequivalence approach.

B. The test and reference products in the same packaging configuration (tube or pump) should be physically and structurally similar based upon an acceptable comparative physicochemical characterization of a minimum of three batches of the test and three batches (as available) of the reference product. The test and reference product batches should ideally represent the product at different ages throughout its shelf-life. The comparison of the test and reference products should include characterizations of the following physical and structural attributes:

   i. Assessment of visual appearance
   
   ii. Microscopic examination with representative high resolution microscopic images at multiple magnifications
   
   iii. Analysis of globule size distribution
   
   iv. Analysis of the rheological behavior which may be characterized using a rheometer that is appropriate for monitoring the non-Newtonian flow behavior of semi-solid dosage forms. The following evaluations are recommended:
• A characterization of shear stress vs. shear rate and viscosity vs. shear rate. At minimum, this should consist of numerical viscosity data at three shear rates (low, medium, and high), and may include a complete flow curve across the range of attainable shear rates, until low or high shear plateaus are identified (when possible).

• Yield stress values should be reported if the material tested exhibits plastic flow behavior.

• The linear viscoelastic response (storage and loss modulus vs. frequency) should be measured and reported.

v. Analysis of pH, specific gravity, and any other potentially relevant physical and structural similarity characterizations

C. The test and reference products in the same packaging configuration (tube or pump) should have an equivalent rate of oxymetazoline release based upon an acceptable in vitro release test (IVRT) comparing a minimum of one batch each of the test and reference products using an appropriately validated IVRT method. Refer to the Guidance on Acyclovir (for acyclovir topical cream, 5%)\(^1\) for additional information regarding the development, validation, conduct, and analysis of acceptable IVRT methods/studies. The batches of test and reference products evaluated in the IVRT study should be included among those for which the physical and structural similarity is characterized and compared.

D. The test and reference products in the same packaging configuration (tube or pump) should have an equivalent rate and extent of oxymetazoline permeation through excised human skin based upon an acceptable in vitro permeation test (IVPT) comparing a minimum of one batch each of the test and reference products in the same packaging configuration (tube or pump) using an appropriately validated IVPT method. Refer to the Guidance on Acyclovir (for acyclovir topical cream, 5%)\(^1\) for additional information regarding the development, validation, conduct, and analysis of acceptable IVPT methods/studies. The batches of test and reference products evaluated in the IVPT study should be the same as those evaluated in the IVRT study.

---

**Analytes to measure (in appropriate biological fluid):** Oxymetazoline in IVPT receptor solution

**Bioequivalence based on (90% CI):** Oxymetazoline

**Waiver request of in vivo testing:** Not applicable

**Dissolution test method and sampling times:** Not applicable

---

\(^1\) Guidance on Acyclovir for acyclovir topical cream, 5%

Recommended Nov 2019 2
2. **Option 2: In vivo study with clinical endpoint**

   Type of study: Bioequivalence study with clinical endpoint  
   Design: Randomized, double blind, parallel, placebo controlled in vivo  
   Strength: 1%  
   Subjects: Males and nonpregnant, nonlactating females with moderate to severe persistent facial erythema of rosacea  
   Additional comments: Specific recommendations are provided below.

---

**Anlytes to measure (in appropriate biological fluid):** Not applicable

**Bioequivalence based on (90% CI):** Clinical endpoint

**Waiver request of in vivo testing:** Not applicable

**Dissolution test method and sampling times:** Not applicable

---

**Additional comments regarding the bioequivalence study with clinical endpoint:**

1. The Office of Generic Drugs recommends conducting a bioequivalence study with clinical endpoint in the treatment of moderate-to-severe persistent facial erythema of rosacea. The study should compare the test product versus the reference product and placebo (vehicle) control, each administered by applying a pea-size amount of the assigned study treatment to each of the five areas of the face (forehead, chin, nose, each cheek)—avoiding the eyes and lips—once daily for 15 days.

2. A placebo (vehicle) control arm is recommended to demonstrate that the test product and reference product are active and as a parameter to establish that the study is sufficiently sensitive to detect differences between products.

3. Inclusion criteria (the sponsor may add additional criteria):
   a. Male or nonpregnant, nonlactating females aged at least 18 years
   b. A clinical diagnosis of facial rosacea
   c. Moderate to severe persistent facial erythema associated rosacea at baseline, as determined by:
      - A Clinician Erythema Assessment (CEA) score of $\geq 3$ at Screening and on Baseline/Day 1 prior to study drug application (per Table 1)
      - A Patient’s Self-Assessment (PSA) score of $\geq 3$ at Screening and on Baseline/Day 1 prior to study drug application (per Table 2)
Table 1: Sample CEA Scale for Rosacea

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Clear skin with no signs of erythema</td>
</tr>
<tr>
<td>1</td>
<td>Almost clear; slight redness</td>
</tr>
<tr>
<td>2</td>
<td>Mild erythema; definite redness</td>
</tr>
<tr>
<td>3</td>
<td>Moderate erythema; marked redness</td>
</tr>
<tr>
<td>4</td>
<td>Severe erythema; fiery redness</td>
</tr>
</tbody>
</table>

Table 2: Sample PSA Scale for Rosacea

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No redness</td>
</tr>
<tr>
<td>1</td>
<td>Very mild redness</td>
</tr>
<tr>
<td>2</td>
<td>Mild redness</td>
</tr>
<tr>
<td>3</td>
<td>Moderate redness</td>
</tr>
<tr>
<td>4</td>
<td>Severe redness</td>
</tr>
</tbody>
</table>

d. Subject’s willingness to minimize external factors that might trigger rosacea flare-ups (e.g., spicy foods, thermally hot foods and drinks, hot environments, prolonged sun exposure, strong winds, alcoholic beverages)

4. Exclusion criteria (the sponsor may add additional criteria):
   a. Females who are pregnant, breast feeding, or planning a pregnancy
   b. Females of childbearing potential who do not agree to utilize an adequate form of contraception
   c. Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.
   d. Presence of ≥ 3 facial inflammatory lesions of rosacea
   e. Subjects with Raynaud’s syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren’s syndrome, or depression
   f. Presence of any skin condition on the face that would interfere with the diagnosis or assessment of rosacea
   g. Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that would interfere with the study treatments or study assessments
   h. Dermatologic or surgical procedure on the face within four weeks prior to baseline
   i. Known hypersensitivity reaction to any component of oxymetazoline therapy
   j. Current use of monoamine oxidase (MAO) inhibitors, barbiturates, opiates, sedatives, systemic anesthetics, alpha-agonists, cardiac glycosides, beta blockers, other antihypertensive agents, or brimonidine tartrate ophthalmic solution
k. Use within six months prior to baseline of oral retinoids (e.g., Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed)
l. Use within 12 weeks prior to baseline of systemic immunomodulators
m. Use within four weeks prior to baseline of 1) topical immunomodulators, 2) systemic antibiotics, 3) systemic corticosteroids, 4) systemic anti-inflammatory agents, 5) systemic treatment for rosacea, or 6) systemic treatment for acne (other than oral retinoids, which require a 6-month washout)
n. Use within two weeks prior to baseline of 1) topical corticosteroids, 2) topical antibiotics, 3) topical anti-inflammatory, 4) topical treatment for rosacea, or 6) topical treatment for acne
o. Use within 1 week prior to baseline of niacin ≥ 500 mg per day

5. The protocol should include a list of the prescription and over-the-counter drug products, procedures, and activities that are prohibited during the study, such as:
a. Any other topical products applied to face.
b. Medicated soaps used on face.
c. Dermatologic or surgical procedure on face.
d. MAO inhibitors, barbiturates, opiates, sedatives, systemic anesthetics, alpha-agonists, cardiac glycosides, beta blockers, other antihypertensive agents, or brimonidine tartrate ophthalmic solution.
e. Systemic treatment for rosacea.
f. Systemic corticosteroids, systemic antibiotics, systemic immunomodulators, systemic anti-inflammatory agents, oral retinoids, or other systemic treatment for acne vulgaris.
g. Use of tanning booths, sunbathing, or excessive exposure to the sun.
h. Subjects should be instructed to wash their hands with soap and water before and after applying treatment and to avoid contact of the study product with the eye or lips.

6. The CEA should be performed at the screening visit, the Baseline/Day 1 visit, and the End of Study/Day 15 visit. The screening visit and the Day 1 visit should be on separate days. During the screening visit, the CEA and PSA should be performed once. During the Day 1 and Day 15 visits, the CEA should be performed five times: prior to dosing and at 3, 6, 9, and 12 hours post-application.

7. The recommended primary endpoint is the proportion of subjects with treatment success at Hour 3, 6, 9, and 12 post-application on Day 15, where treatment success is defined as a 2-grade improvement from pre-dose on Day 1 on CEA only. During the assessment of Day 15, investigators should evaluate CEA in comparison to Baseline assessment of the subjects’ erythema (e.g., CEA scores, photographs).

8. Provide the Subject-Level Analysis Dataset (ADSL), one record per subject, using the following headings, if applicable:
a. Study identifier
b. Unique subject identifier
c. Subject identifier for the study
d. Study site identifier (if applicable)
e. Age
f. Age units (years)
g. Sex
h. Race
i. Name of planned treatment
j. Name of actual treatment
k. Safety population flag (yes/no)
l. Reason for exclusion from safety population
m. Modified Intent-to-Treat (mITT) population flag (yes/no)
n. Reason for exclusion from mITT population
o. Per-Protocol (PP) population flag (yes/no)
p. Reason for exclusion from PP population
q. Randomized population flag (yes/no)
r. Date/time of first exposure to treatment
s. Date/time of last exposure to treatment
t. End of study date
u. End of study status
v. Subject required additional treatment due to unsatisfactory treatment response (yes/no)
w. CEA score at screening visit
x. PSA score at screening visit
y. CEA score at Day 1 visit at pre-dose
z. PSA score at Day 1 visit at pre-dose
aa. CEA score at Day 1 visit at 3 hours post-application
bb. CEA score at Day 1 visit at 6 hours post-application
cc. CEA score at Day 1 visit at 9 hours post-application
dd. CEA score at Day 1 visit at 12 hours post-application
e. CEA score at Day 15 visit at pre-dose
ff. CEA score at Day 15 visit at 3 hours post-application
gg. CEA score at Day 15 visit at 9 hours post-application
hh. CEA score at Day 15 visit at 12 hours post-application
ii. Compliance rate (%)
jj. Subject missed the pre-specified number of scheduled doses for more than pre-specified number of consecutive days (yes/no)
kk. Adverse event reported (yes/no)
ll. Concomitant medication (yes/no)

9. Provide the basic data structure (BDS) dataset with records per subject, per visit, per analysis timepoint, using the following headings, if applicable:

a. Study identifier
b. Unique subject identifier
c. Subject identifier for the study
d. Study site identifier (if applicable)
e. Name of planned treatment
f. Name of actual treatment
g. Safety population flag (yes/no)
h. Modified ITT population flag (yes/no)
i. Per-Protocol (PP) population flag (yes/no)
j. Analysis date
k. Analysis visit
l. Study visit within the designated window (yes/no)
m. Analysis timepoint (e.g., hour 0, hour 3, 6, 9, and 12 hours post-application)
n. CEA score
o. PSA Score
p. Additional treatment required during the visit (yes/no)
q. Adverse event reported during the visit (yes/no)
r. Concomitant medication during the visit (yes/no)

10. Please refer to the product-specific guidance on adapalene; benzoyl peroxide topical gel 0.3%; 2.5% entitled Guidance on Adapalene; Benzoyl Peroxide for a recommended approach to statistical analysis and study design for bioequivalence studies with clinical endpoints.

11. Study data should be submitted in a standardized format. Please refer to the study data standards published at www.fda.gov. 

\[\text{www.fda.gov}^2\]

---

\[^2\] Study Data Standards for Submission to CDER and CBER available at: https://www.fda.gov/industry/study-data-standards-resources/study-data-submission-cder-and-cber